0001209191-23-036127.txt : 20230609
0001209191-23-036127.hdr.sgml : 20230609
20230609211639
ACCESSION NUMBER: 0001209191-23-036127
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230608
FILED AS OF DATE: 20230609
DATE AS OF CHANGE: 20230609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Leheny A. Rachel
CENTRAL INDEX KEY: 0001484729
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39538
FILM NUMBER: 231006937
MAIL ADDRESS:
STREET 1: C/O ANTHERA PHARMACEUTICALS, INC.
STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B
CITY: HAYWARD
STATE: CA
ZIP: 94545
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CalciMedica, Inc.
CENTRAL INDEX KEY: 0001534133
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452120079
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 505 COAST BOULEVARD SOUTH
STREET 2: SUITE 307
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: 858-952-5500
MAIL ADDRESS:
STREET 1: 505 COAST BOULEVARD SOUTH
STREET 2: SUITE 307
CITY: LA JOLLA
STATE: CA
ZIP: 92037
FORMER COMPANY:
FORMER CONFORMED NAME: CalciMedica, Inc. /DE/
DATE OF NAME CHANGE: 20230322
FORMER COMPANY:
FORMER CONFORMED NAME: GRAYBUG VISION, INC.
DATE OF NAME CHANGE: 20170717
FORMER COMPANY:
FORMER CONFORMED NAME: GRAYBUG, Inc.
DATE OF NAME CHANGE: 20150303
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-08
0
0001534133
CalciMedica, Inc.
CALC
0001484729
Leheny A. Rachel
C/O CALCIMEDICA, INC.
505 COAST S. BLVD. #202
LA JOLLA
CA
92037
1
1
1
0
Chief Executive Officer
0
Common Stock
2023-06-08
4
P
0
928
5.2269
A
8928
D
Common Stock
2023-06-09
4
P
0
400
5.25
A
9328
D
Common Stock
1000
I
By Spouse
Common Stock
356989
I
By Valence Investments SPV IV, LLC
Common Stock
66228
I
By Valence Investments SPV V, LLC
Common Stock
316109
I
By Valence Investments SPV VI, LLC
The weighted average purchase price for the transaction reported was $5.2269, and the range of prices were between $5.20 and $5.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein.
By John Dunn, Attorney-in-Fact
2023-06-09